Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Heart Test Laboratories Inc. Common Stock (HSCS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HSCS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $13.5
1 Year Target Price $13.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.49% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.85M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 2 | Beta 2.58 | 52 Weeks Range 2.36 - 6.47 | Updated Date 08/15/2025 |
52 Weeks Range 2.36 - 6.47 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.34 |
Earnings Date
Report Date 2025-07-24 | When - | Estimate -0.03 | Actual -1.96 |
Profitability
Profit Margin - | Operating Margin (TTM) -44147.1% |
Management Effectiveness
Return on Assets (TTM) -76.07% | Return on Equity (TTM) -233.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9742361 | Price to Sales(TTM) 1805.72 |
Enterprise Value 9742361 | Price to Sales(TTM) 1805.72 | ||
Enterprise Value to Revenue 2239.62 | Enterprise Value to EBITDA -0.14 | Shares Outstanding 2244250 | Shares Floating 1861590 |
Shares Outstanding 2244250 | Shares Floating 1861590 | ||
Percent Insiders 4.13 | Percent Institutions 1.54 |
Upturn AI SWOT
Heart Test Laboratories Inc. Common Stock
Company Overview
History and Background
Heart Test Laboratories, Inc. (HSCS) is a medical technology company focused on preventing heart attacks through early detection using a patented, non-invasive, AI-driven diagnostic tool. The company was incorporated in 2016 and is headquartered in Southlake, Texas.
Core Business Areas
- MyoVistau00ae: The MyoVistau00ae is a resting 12-lead ECG that combines advanced signal processing techniques with AI to detect subtle changes in the heart's electrical activity, potentially identifying at-risk patients earlier than traditional ECGs. The MyoVista is the main product of the company and the company is looking to expand on its capabilities.
Leadership and Structure
Andrew Simpson serves as the Chief Executive Officer. The company is structured with a Board of Directors overseeing management.
Top Products and Market Share
Key Offerings
- MyoVistau00ae: The MyoVistau00ae is a resting 12-lead ECG that uses AI to detect potential heart issues early. Market share is still small as the company is in the early stages of commercialization. Competitors include established ECG manufacturers such as GE Healthcare, Philips, and Nihon Kohden, as well as emerging companies focusing on AI-enhanced cardiac diagnostics.
Market Dynamics
Industry Overview
The cardiovascular diagnostics market is experiencing growth driven by the increasing prevalence of heart disease and advancements in technology, particularly AI and machine learning. There is a growing demand for non-invasive and early detection methods.
Positioning
Heart Test Laboratories Inc. is positioned as an innovator in the cardiac diagnostics space, offering a non-invasive AI-powered solution for early heart disease detection. Its competitive advantage lies in its patented technology and focus on preventive care.
Total Addressable Market (TAM)
The global cardiac monitoring & diagnostic devices market is estimated to be multi-billion dollar market. Heart Test Laboratories Inc. targets a portion of this market by focusing on the early detection and prevention segment. HSCS aims to capture significant market share through the MyoVista's advanced AI capabilities.
Upturn SWOT Analysis
Strengths
- Patented AI-driven technology
- Non-invasive diagnostic tool
- Focus on early heart disease detection
- Potential for cost savings through preventive care
Weaknesses
- Limited commercialization to date
- Dependence on single product (MyoVistau00ae)
- Requires significant capital for marketing and sales expansion
- Limited data to support improved patient outcomes
Opportunities
- Partnerships with healthcare providers and insurance companies
- Expansion into international markets
- Development of new AI-driven diagnostic tools
- Increased awareness of preventive cardiology
Threats
- Competition from established medical device companies
- Regulatory hurdles and approval processes
- Reimbursement challenges from insurance providers
- Potential for technological obsolescence
Competitors and Market Share
Key Competitors
- GE (GE)
- Philips (PHG)
- Nihon Kohden (6849.T)
Competitive Landscape
Heart Test Laboratories Inc. is a smaller player in a market dominated by established medical device companies. Its competitive advantage lies in its AI-driven technology, but it faces challenges in terms of market access and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited given the company's early stage. Focus on recent sales data and market penetration.
Future Projections: Future growth depends on successful commercialization of the MyoVistau00ae, expansion into new markets, and strategic partnerships. Analyst estimates should be reviewed regularly.
Recent Initiatives: Recent initiatives may include marketing campaigns, partnerships with healthcare providers, and regulatory approvals.
Summary
Heart Test Laboratories Inc. is a very young company with innovative AI technology for early heart disease detection. The company's success relies on commercializing its MyoVistau00ae product, securing partnerships, and navigating regulatory hurdles. Capital needs to be raised for market entry. The company needs to be mindful of strong competitors in the space.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heart Test Laboratories Inc. Common Stock
Exchange NASDAQ | Headquaters Southlake, TX, United States | ||
IPO Launch date 2022-06-15 | CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson | ||
Sector Healthcare | Industry Medical Devices | Full time employees 15 | Website https://heartsciences.com |
Full time employees 15 | Website https://heartsciences.com | ||
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.